Figure 6 | Leukemia

Figure 6

From: E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271

Figure 6

RNA expression of either ST3Gal-4 or ST3Gal-6 and FUT7 greater than the median correlates with inferior survival outcomes. Kaplan–Meier estimates of PFS in MM patients with RNA expression of either ST3Gal-4 or ST3Gal-6, and FUT7 greater than the median (blue) and the remainder of the patients (red) show statistically significant inferior overall PFS times (P-value=0.02), with a hazard ratio of 1.37. Data were generated from the CoMMpass trial. X axis represents time to progression in days and Y axis represents proportion of patients without progression. PFS, progression-free survival.

Back to article page